T lymphocytes recognize Ag-derived peptides presented on the surface of APC in association with MHC molecules. Specific recognition of the large variety of these complexes is achieved through their interaction with clonally distributed ␣␤ TCR. The number of different TCR that the immune system is able to generate through a sophisticated recombination process is theoretically large enough to ensure recognition of any potential complex (1). However, several factors limit both the composition and the size of the actual TCR repertoire. Important constraints to its composition are imposed during thymic selection. Immature thymocytes are "educated" by antigenic self-peptide/ MHC (pMHC) complexes presented on thymic APC (2). Thymocytes recognizing self complexes with high affinity are deleted, whereas those recognizing them with low affinity are selected to undergo further maturation (3) . Thus, recognition of a limited number of self complexes tremendously restricts and shapes the TCR repertoire, with the proportion of positive-selected thymocytes not higher than 5% of the total (4) . The size of the TCR repertoire is first limited by the number of T cells present in an animal (ϳ10 12 in an adult human being). The number of distinct specificities in the TCR repertoire is further limited by the fact that, to mount an appropriate immune response to a given antigenic determinant, a certain number of specific T cells have to be present in the repertoire. Indeed, it has been shown that, in a single individual, many different clonotypes usually contribute to immune responses against an antigenic determinant (5).
Therefore, it is becoming increasingly clear, both from theoretical considerations and experimental evidence, that a high degree of cross-reactivity is a normal feature of the TCR and constitutes an essential characteristic of T cell recognition (6) . However, both the molecular nature and the extent of the cross-reactivity between the pool of natural antigenic determinants and the T cell repertoire are not immediately obvious and most likely vary widely for each antigenic determinant and for each TCR. Indeed, even if flexible, T cell recognition remains exquisitely specific and very small changes can profoundly affect it (7) . These changes do not necessarily need to be located in TCR contact residues of the antigenic peptide but can be due to more-or-less subtle modifications of the MHC/peptide complex conformation, such as variations in the conformation that the peptide itself adopts in the MHC molecule, or even small peptide-dependent variations of the MHC molecule (8 -10) . Moreover, as the relevant conformation can be mimicked by apparently completely unrelated ligands, cross-reactivity does not necessarily imply sequence homology (11, 12) . As a result of this complexity, it is very difficult to predict whether, and to what extent, one antigenic determinant will cross-react with another.
An empirical approach for the identification of antigenic determinants cross-recognized by Ag-specific T cells is based on the analysis of the recognition by clonal T cells of synthetic combinatorial peptide libraries in positional scanning format (PS-SCL 5 ; Ref. 13) . We have recently elaborated a biometric analysis that uses the data generated by screening PS-SCL with T cell clones to analyze and rank all peptides in public protein databases for sequences with predicted reactivity (14) . In this study, we have analyzed the recognition by tumor-reactive CTL specific for an immunodominant peptide from the melanocyte differentiation and tumor-associated Ag Melan-A (15), of peptides retrieved in proteins of self or pathogen origin by using biometric analysis of the data generated by screening of PS-SCL with a Melan-A-specific clone.
Materials and Methods

Scoring matrix and database searches
A scoring matrix was generated by using data previously obtained by screening an amidated C terminus decapeptide PS-SCL (16) with the Melan-A-specific CTL clone LAU 203/1.5 in a functional chromium-release assay. A Z-scoring matrix was generated using the average and SD of the percentage of specific-lysis values of multiple experimental data obtained for each mixture defined with one of the 20 L-amino acids in each of the 10 positions of the decamer library (14) . Based on the assumption of independent and additive contribution of the individual amino acids at each position of a peptide to the peptide's activity, the score of each individual peptide was calculated by adding individual stimulatory values of the composing amino acids. A program was designed to use the matrix to score all overlapping decapeptides contained in the GenPept protein database (ftp:// ftp.ncicfr.gov/pub/genpept) and thus identify sequences with the highest predicted stimulatory scores (14) .
Cells
The Melan-A-specific CTL clone LAU 203/1.5 was derived from tumorinfiltrated lymph node cells of patient LAU 203 by limiting dilution culture in the presence of irradiated allogeneic PBMC, PHA, and human (h)rIL-2 (150 IU/ml; Glaxo, Geneva, Switzerland; kindly provided by Dr. M. Nabholz, Institut Suisse de Recherches Experimentales sur le Cancer, Epalinges, Switzerland) as previously described (17) . Cells were subsequently expanded by periodic (3-to 4-wk) restimulation in microtiter plates together with irradiated feeder cells in the presence of PHA and hrIL-2. Polyclonal Melan-A monospecific CTL lines and other Melan-A specific clones were similarly generated from Melan-A multimer ϩ -sorted cells as previously described (18) . All selected populations were able to specifically lyse Melan-A-expressing melanoma tumor cells. For peptide stimulation of PBMC, CD8 ϩ lymphocytes were positively selected by magnetic cell sorting from PBMC of A2 melanoma patients using a miniMACS device (Miltenyi Biotec, Sunnyvale, CA). Cells of the CD8 Ϫ fraction were irradiated (3000 rad) and used as autologous APC. CD8 ϩ highly enriched lymphocytes (1 ϫ 10 6 ) were stimulated with peptide (1 g/ml) and irradiated autologous APC in 2 ml of IMDM (Life Technologies, Basel, Switzerland) containing 8% pooled human serum, hrIL-2 (100 IU/ml), and hrIL-7 (10 ng/ml, R&D Systems, Oxon, U.K.). Cells underwent an additional cycle of stimulation with peptide-pulsed APC before analysis.
Ag-recognition assay
Ag recognition was assessed in chromium-release experiments. Briefly, target cells were labeled with 51 Cr for 1 h at 37°C and washed three times. Labeled target cells (1000 cells/well) were incubated in the presence of peptide libraries (100 g/ml final) or, in peptide titration experiments, with various peptide doses, for 15 min at room temperature before the addition of effector cells at a lymphocyte-to-target cell ratio of 10:1. Chromium release was measured in supernatants harvested after 4-h incubation at 37°C. The percentage of specific lysis was calculated as: 100 ϫ [(experimental Ϫ spontaneous release)/(total Ϫ spontaneous release)]
Multimers, mAbs, and flow cytometry analysis
A2/peptide multimers incorporating the Melan-A 26 -35 A27L analog (8) or peptides MSI-44 -10 (PT 178 -187), MSI-44 -25 (PV 454 -463), and MSI-44 -56 (CT 51-60) were synthesized as described previously (19) . Cells were stained with multimers PE (4.5 g/ml in 20 l) for 1 h at room temperature, before the addition of anti-CD8 FITC mAb (BD Biosciences, San Jose, CA) and further incubated for an additional 30 min at 4°C. At the end of the incubation period, cells were washed and analyzed by flow cytometry on a FACScan (BD Biosciences). Data analysis was performed using the CellQuest software.
Results
Recognition of self-and pathogen-derived peptides selected on the basis of their potential cross-reactivity with Melan-A by clone LAU 203/1.5
In a previous study, we used the Melan-A-specific and tumorreactive CTL clone LAU 203/1.5 to screen an amidated C terminus decapeptide PS-SCL, (16) in a functional chromium release assay (CTL assay). Based on those results, in this study, we performed a biometric data analysis (as recently reported (14) and further detailed in Materials and Methods) that allows the use of the results of the PS-SCL screening to search for potentially cross-reactive sequences in public protein databases. As illustrated in Table I, our search retrieved 21 peptides of self origin and 25 peptides of viral origin with higher predicted T cell stimulatory values (scores) than the parental Melan-A 26 -35 decapeptide (MSI-44 -22, Table I ). These peptides were selected for analysis. Among peptides of bacterial origin, a high number (280) scored higher than Melan-A 26 -35 . Of those, the first 25 peptides were selected for analysis. For consistency with the PS-SCL used for the screening, peptides were synthesized with amidated C termini. Recognition of the selected peptides by the CTL clone LAU 203/1.5 was initially tested at a single peptide dose (1 g/ml) in a CTL assay. An example of the data obtained is illustrated in Fig. 1A . Data obtained for all peptides tested and a summary thereof are reported in Fig.  1 , B and C, respectively. Specific lysis of Ͼ10% was considered significant, because values Ͻ10% were consistently obtained for a group of 100 unrelated peptides similarly tested (data not shown). Thirty-nine percent of the selected peptides were significantly recognized by clone LAU 203/1.5 (Fig. 1C) . It is noteworthy that the proportion of peptides recognized was higher among those of bacterial origin than those of self or viral origin. The relative efficiency of recognition of the selected peptides was further assessed by performing peptide titrations as illustrated in Fig. 2A . Results are summarized in Fig. 2B . Of the 28 peptides recognized by clone LAU 203/1.5, 12 were recognized with roughly comparable efficiency (relative recognition Ͻ10 but Ͼ0.1), as compared with Melan-A 26 -35 ; 4 were recognized significantly more efficiently (relative recognition of Ն10); and the remaining 12 were recognized significantly less efficiently (relative recognition of Յ0.1). Cross-reactivity between amidated and free C termini peptides was tested for a group of peptides selected among the most active ones. As summarized in Fig. 2C and consistent with our previous data (20) , peptides bearing free C termini were generally recognized as well as or more efficiently than their amidated C termini counterparts, although to a variable extent.
Recognition of PS-SCL-retrieved peptides is more frequent among predicted A2 binders of higher affinity than Melan-A 26 -35 and among peptides with the highest scores To elucidate the factors impacting on the recognition of the selected peptides by clone LAU 203 1.5, their potential binding capacity to A2 was first determined using an algorithm that calculates the theoretical dissociation rate of the corresponding A2/ peptide complexes based on their amino acid composition (available at the Bioinformatics and Molecular analysis section of the National Institutes of Health website, http://bimas.dcrt.nih.gov/ molbio/hla_bind/) (21) . As expected from both the absence of canonical "anchor residues" and our previous experimental data (8, 17, 22) , peptide Melan-A 26 -35 was predicted as a relatively poor binder (theoretical t 1/2 of ␤ 2 m dissociation was around 3300-fold lower than for a known good A2 binder, peptide Flu-MA 58 -66 , supplemental data, Table II ). Among the selected peptides, 35% had a relative predicted binding lower than that of Melan-A 26 -35 , whereas the majority (65%) had a similar or higher (up to Ͼ20,000-fold) predicted binding value. Interestingly, the frequency of peptides recognized by clone LAU 203/1.5 was high (89%; Fig. 3A ) among peptides with relative predicted binding equal to or greater than that of Melan-A 26 -35 . Indeed, only 13% of peptides with predicted binding lower than that of Melan-A 26 -35 were significantly recognized, whereas about half (47%) of peptides with predicted binding equal to or greater than that of Melan-A 26 -35 were significantly recognized (Fig. 3A) . In addition, all of the peptides that were recognized more efficiently than the parental Melan-A peptide had a higher predicted A2 binding value (Fig.  3B ). Relative predicted binding was independent from peptide score (the mean score was similar in the two groups, Fig. 3C ), consistent with the peptide selection procedure used that was, in this sense, completely unbiased. However, when peptides were divided into two groups according to whether their scores were higher or lower than the mean score of all peptides tested (Fig.  3D) , ϳ70% of the peptides in the high scoring group were recognized. In addition, 75% of the peptides that were recognized more efficiently than the parental Melan-A peptide belonged to the group with the highest scores (Fig. 3E ). To compare predicted to experimental binding, experimental binding was assessed in a functional competition assay as described previously (17) for peptides available in the terminal C-free form (Fig. 2C) . The experimental values obtained were consistent with predicted binding values (not shown).
A large proportion of PS-SCL-retrieved peptides are crossrecognized by other Melan-A-specific CTL
We next investigated whether cross-recognition of the selected peptides was found only for clone LAU 203/1.5 or also for other Melan-A-specific CTL.
To this end, we tested their recognition by a large panel of Melan-A-monospecific CTL lines (18) and clones derived from four melanoma patients (LAU 203, LAU 337, LAU 455, and LAU 465) and one healthy donor (HD 421). Our previous studies of the TCR repertoire of Melan-A-specific CTL have shown that the latter is extremely large and diverse and mostly nonoverlapping between different individuals (5, 23) . Thus, the majority of Melan-A-specific CTL clones used in this study are likely to express different TCR. In addition, TCR sequences were previously determined in the case of CTL clones from LAU 337 (24) and HD 421 (25) , and all were found to be distinct. Results obtained are shown in Table III and summarized in Tables IV and  V . Surprisingly, we found a degree of cross-reactivity that was higher than that of clone LAU 203/1.5. Indeed, the proportion of peptides recognized by at least one of the CTL populations analyzed accounted for 94% of the total (Table IV) . Melan-A-specific clones largely differed in terms of their ability to cross-recognize the peptides, ranging from no detectable cross-recognition by clone LAU 337/6C3 to recognition of 68% (48/71) of the peptides by clone LAU 337/2A5 (Table V) . Polyclonal monospecific lines generally displayed a higher degree of cross-recognition as compared with CTL clones, possibly because of the combined reactivity of clonal populations composing these lines. The polyclonal monospecific population derived from patient LAU 203 cross-recognized a higher proportion of peptides (68%) than did clone LAU 203/1.5. It is of note that, in contrast with the data obtained for clone LAU 203/1.5 (Fig. 3A) , there was no correlation between the ability of the peptides to be recognized by different Melan-A-specific CTL and their A2-binding capacity (Fig. 3F) . Interestingly, some peptides were recognized by the majority of CTL (i.e., MSI-44 -25, Table IV ). To further explore the extent of cross-reactivity between these peptides (in particular those most frequently recognized by Melan-A-specific CTL) and Melan-A, we synthesized A2/peptide multimers incorporating three of the most frequently recognized peptides, one of self origin (peptide PT 178 -187 from PG transporter), one of viral origin (peptide PV 454 -463 from the glycoprotein GIII precursor of pseudorabies virus), and one of bacterial origin (peptide CT 51-60 from the arginine/ornithine antiporter of Chlamydia trachomatis). These multimers specifically stained clone LAU 203/1.5 but not clones of unrelated specificity; in addition, they were able to specifically stain ex vivo a significant proportion of circulating CD8 ϩ T cells from patient LAU 203, similar to what had been observed previously with multimers incorporating a Melan-A 26 -35 analog A27L (Ref. 26 and data not shown).
Melan-A-related peptides frequently recognized by specific CTL are immunogenic in vitro and elicit heterogeneous CTL responses partially cross-reactive with Melan-A
To determine whether the peptides frequently cross-recognized by Melan-A-specific CTL could elicit CTL responses cross-reactive with Melan-A, we used three of the most frequently cross-recognized peptides to stimulate in vitro highly enriched CD8 ϩ T lymphocytes from melanoma patients. As internal controls, we included CD8 ϩ T cells cultured under the same conditions, but in the absence of any exogenously added peptide, or stimulated with Melan-A 26 -35 parental peptide or with the analog Melan-A 26 -35 A27L. Consistent with our previous data (27) , stimulation with the analog Melan-A 26 -35 A27L elicited a specific response significantly higher than that observed with the Melan-A 26 -3 5 parental peptide for all patients (Fig. 4, A and B) . Importantly, as illustrated in Fig. 4A for patient LAU 241, each of the three selected peptides elicited an even stronger response when tested with multimers incorporating the peptide used for in vitro stimulation (autologous multimers), whereas a lower, but very significant, proportion of CD8 ϩ Melan-A 26 -35 A27L multimer ϩ cells were detected in each of these cultures. Similar results were obtained in the case of two additional melanoma patients (Fig. 4B) and two healthy donors (not shown). To further dissect the heterogeneity of the CTL response elicited by Melan-A related peptides, CD8 ϩ autologous multimer ϩ cells from each culture were isolated by cell sorting, expanded in vitro with PHA, and stained again with multimers incorporating either the autologous peptide or peptide Melan-A 26 -35 A27L. In each case, the resulting populations were homogeneously stained by autologous multimers, whereas only part of these cells were stained by multimers incorporating peptide Melan-A 26 -35 A27L (Fig. 5A ). CD8
ϩ Melan-A 26 -35 A27L multimer ϩ and multimer Ϫ cell fractions were further isolated from each culture by cell sorting, and their activity was analyzed in CTL assay. As illustrated in Fig. 5B for one of the cultures and summarized in Fig. 5C for all tested cultures from two melanoma patients, CD8
ϩ Melan-A 26 -35 A27L multimer ϩ fractions crossrecognized peptide Melan-A 26 -35 A27L much more efficiently y-axis) . B, Relative predicted binding is plotted against the efficiency of recognition of each peptide (calculated as in Fig. 2B) . C, Relative predicted binding is plotted against peptide score. D, Peptide score is plotted against specific lysis (as in A). E, Peptide score is plotted against relative recognition (as in B). F, Relative predicted binding is plotted against percentage of specific CTL that recognize each peptide (Table III) . 
a Peptide recognition was assessed as in Fig. 1 . ϩ, Ͼ10% specific lysis; ϩϩ, Ͼ20% specific lysis; ϩϩϩ, Ͼ40% specific lysis; ϩϩϩϩ, Ͼ60% specific lysis. 
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ϩ Melan-A 26 -35 A27L multimer Ϫ fractions. In contrast, the peptide used for the in vitro stimulation was generally recognized by both fractions with roughly similar efficiency (Fig. 5C ). Importantly, a low but significant level of specific lysis of Melan-A ϩ A2 ϩ tumor cells was detected for the majority of the tested cultures and mostly segregated with the CD8 ϩ Melan-A 26 -35 A27L multimer ϩ fractions (Fig. 5D ).
Discussion
The identification of natural peptide sequences cross-recognized by clinically relevant T cell clones is of great interest for both the understanding of T cell repertoire selection and maintenance, as well as for immunotherapeutic purposes. In a review article of T cell cross-reactivity, Mason (6) estimated that a single T cell can productively interact with as many as 10 6 different MHC/peptide complexes. Despite this high degree of cross-reactivity and taking into account the large number of possible MHC-associated peptides (from 10 10 for 9-mers to 10 12 for 11-mers) the chances to identify a peptide cross-recognized by a given TCR among randomly selected peptides is theoretically less than one in 10 4 . Therefore, it is necessary to design targeted methodologies that allow the rapid identification of such sequences. In this study, we tested the predictive potential of our recently described PS-SCL biometric data analysis (14) to use data previously generated by screening a PS-SCL with a Melan-A-specific CTL clone (16) to identify Melan-A cross-reactive sequences in a public protein database. It is of note that, in contrast to other approaches, no information on the parental sequence is required for this type of analysis, which could have been similarly performed for a clinically relevant T cell clone of unknown specificity. In addition, as this analytical approach is exclusively based on functional data and not on sequence homology between parental and cross-reactive peptides, it also allows the identification of cross-reactive peptides with totally unrelated sequences.
Validation of the high predictive value of our analytical approach came from the finding that a high proportion of the peptides analyzed, including sequences with the highest stimulatory scores of either self, viral, or bacterial origin, were recognized by the CTL clone used for the initial PS-SCL screening. It is noteworthy that recognition was highly specific as none of 100 unrelated peptides was significantly recognized (not shown). Reactive peptides were recognized with variable efficiency; remarkably, however, more than half of them were recognized with similar or higher efficiency as compared with the Melan-A parental decapeptide. Further support for the validity of our approach came from the correlation found between predicted stimulatory scores and peptide recognition. It is of note that the most active peptides were identified among peptides of bacterial origin, in good agreement with the higher predicted stimulatory score of this group. In addition, and interestingly, we also found a clear correlation between the relative predicted A2 binding efficiency of the retrieved peptides and their recognition. Thus, although a good A2 binding did not necessarily predict cross-recognition, omitting from the screening peptides with extremely poor predicted binding capacity would have further improved the likelihood of identifying peptides cross-recognized by the CTL clone used for the PS-SCL screening.
A surprising finding of this study was that a much higher proportion of peptides were cross-recognized by Melan-A-specific tumor-reactive CTL other than clone LAU 203/1.5 as compared with clone LAU 203/1.5 itself. However, the extent of cross-recognition was extremely variable among clones, ranging from no detectable cross-recognition (i.e., for clone LAU 337/6C3) to cross-recognition of 68% of the analyzed peptides (i.e., for clone LAU 337/ 2A5). Remarkably, these two clones recognized Melan-A peptides with comparable efficiency (24); thus, a difference in functional avidity of Ag recognition did not account for the different extent of cross-recognition, which could be due to differences in the fine specificity of Ag recognition of the clones analyzed. However, an alternative explanation could be that the different Melan-A-specific clones analyzed differ in terms of "degeneracy" of Ag recognition, e.g., in their capability to productively interact with a more-or-less large number of MHC/peptide complexes. The concept of "degeneracy" of Ag recognition (13) originates from the elucidation of the molecular interactions leading to T cell activation. It is based on the fact that, as underlined by the close inspection of crystal structures of TCR complexes with their MHC/peptide ligands (28, 29) , most of the TCR contacts with the MHC/peptide complex are made with the MHC molecule rather than with the peptide. Thus, the majority of the TCR-MHC/peptide complex binding energy is determined by the affinity of a given TCR for the MHC molecule, the role of the peptide being only to modulate the latter and possibly to raise it beyond the threshold required for T cell activation. It follows that, if the TCR affinity for the MHC molecule is relatively low, the threshold can be attained with only few peptides and Ag recognition appears as highly selective. If, instead, the TCR affinity for the MHC is relatively high, activation is achieved by a relatively high number of different peptides and the TCR appears more "degenerate." Whether, and to what extent, peptides cross-recognized by the more degenerate TCR need to be structurally related is yet undetermined; however, it can be expected that at least a fraction of these peptides share some common structural and/or sequence features. In agreement with this hypothesis, while the strategy used to find Melan-A cross-reactive peptides was not conducted by searching for sequence homologies, the search appears to have yielded a group of cross-reactive peptides, the majority of which share significant internal homology, particularly in the central part of the peptide (position 3 to 7) . Thus, our search may have retrieved a "family" of Melan-A-related sequences, only part of which achieve the threshold of activation for clone LAU 203/1.5, whereas others achieve it only for more degenerate Melan-A-specific CTL.
Related to this is another important question on the modality of T cell cross-recognition. It has indeed not yet been established whether, and to what extent, T cell cross-recognition is focused or unfocused (6), i.e., whether or not distinct T cell clonotypes specific for the same Ag cross-recognize the same set of peptides. Whether cross-reactivity is focused or unfocused has important implications for the potential breaking of self-tolerance as the result of immune responses to foreign Ags. Indeed, if cross-reactivity is unfocused, the fortuitous cross-reaction between a foreign and a self peptide would lead to the expansion of a single or of a limited number of T cell clonotypes, whereas, in the opposite case, it could rapidly lead to a generalized autoimmune reaction. In this regard, the data obtained in this study support the latter hypothesis, as cross-reactivity was, in this case, at least partially focused. Indeed, although some peptides were recognized by only a few clonotypes, others were cross-recognized by the majority of Melan-A-specific CTL. The more frequently recognized peptides shared significant internal homology with Melan-A, particularly in the central part of the peptide. In contrast with the data obtained with the CTL clone used for the initial PS-SCL screening, there was no obvious correlation between the capacity of Melan-A-related sequences to be recognized by different Melan-A-specific CTL and the efficiency of their binding to A2. This indicates that cross-recognition of Melan-A-related peptides by different Melan-A-specific CTL is impacted more by the presence of TCR contact residues in the core region of the peptide than by their A2 binding efficiency. In addition, and importantly, in good agreement with recognition data, stimulation of PBMC from melanoma patients with the more frequently cross-recognized peptides elicited vigorous CTL responses that were at least partially cross-reactive with Melan-A.
It has been previously reported that Melan-A-like sequences are relatively frequent in proteins (30) , possibly because the localization of this peptide in the transmembrane region of the Melan-A protein results in an amino acid composition that may be frequent in hydrophobic regions from other proteins. Thus, it could be argued that the high rate of cross-reactive sequences identified in this study is related to the high frequency of Melan-A-like sequences in proteins and that a very different result could be obtained for other epitopes. To address this point we have recently performed a similar analysis for an HLA-A2-restricted epitope from the cancer testis Ag SSX-2 (31). Interestingly, we found that the majority of retrieved sequences were cross-recognized by the CTL clone used for the PS-SCL screening (D. Valmori, manuscript in preparation), thus supporting the applicability of this approach to epitopes other than Melan-A.
What is the physiologic relevance of the Melan-A cross-reactive sequences? Melan-A cross-reactive peptides of self origin that are recognized by Melan-A-specific CTL with comparable or higher efficiency than Melan-A parental peptides are most likely not presented by thymic APC, as this would result in the deletion of Melan-A-specific thymocytes. In contrast, Melan-A-related self sequences that are recognized weakly or are able, when associated to an MHC molecule, to engage the TCR without leading to T cell activation (antagonists) may play a role in thymic positive selection of Melan-A-specific T cell precursors as well in the maintenance of the peripheral pool of Melan-A-specific T cells. Melan-A-related sequences of pathogen origin could be involved in the pathogenesis of vitiligo, a common progressive depigmentary condition of unknown etiology that is due to the autoimmune destruction of skin melanocytes. The spontaneous appearance of vitiligo has been associated with a favorable prognosis in melanoma patients (32, 33) . Interestingly, higher frequencies of A2/Melan-A multimer ϩ cells have been found in individuals with autoimmune vitiligo as compared with healthy controls (34) . In this respect, it is noteworthy that our search retrieved 25 viral and 280 bacterial peptide sequences with higher predicted stimulatory values than Melan-A. . Interestingly, some of these sequences were derived from common human pathogens and are thus of clear interest for investigating a potential pathogen-related etiology of vitiligo. Finally, it is of note that the Melan-A cross-reactive peptides identified in this study most likely represent only a small subgroup of the existing ones and are not necessarily among the most relevant. Depending on the likely rapid improvement of relevant technologies, it will be of great interest, in future studies, to extend this analysis to a large number of peptides, possibly selected from the ones that are naturally processed and presented, to unveil the most relevant cross-reactivity between Melan-A and the universe of peptides encoded by human and pathogen genomes.
In conclusion, the findings reported in this study strongly encourage the use of this methodology, which combines PS-SCL screening with T cell clones of interest and includes biometric analysis of the generated data, to further elucidate the molecular basis of T cell cross-reactivity. In addition, the reported data validate the predictive value of this approach for identifying in public protein databases the sequence of natural peptides cross-recognized by clinically relevant T cells.
